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Background: Hereditary angioedema (HAE) resulting from C1-inhibitor deficiency is characterized by attacks of
subcutaneous and submucosal edema. Many factors have been presumed to induce edema. Our study analyzed
these factors in a fairly large patient population.
Methods: In the first stage of our study, we analyzed the data recorded by 92 subjects in their patient diaries over
seven years. The second phase included 27 HAE patients, who had been completing the diary entry ‘Trigger factors’
every day for seven months whether or not they had experienced an attack.
Results: During the initial stage, 91% of the subjects described some factor possibly related to the onset of an
attack. They could identify a trigger factor – most commonly (21%) mental stress – in 30% of the 3176 attacks.
We found a significant (p < 0.001) difference in the distribution of the trigger factors of the edematous attacks of
different locations. The 27 participants of the second phase identified 882 potential trigger factors and recorded
365 attacks. Of these, 246 (67%) occurred on days when the patients identified a potential trigger factor. The
likelihood of edema-formation associated with the latter was as follows: menstruation – 63%, infection – 38%,
mental stress – 26%, physical exertion – 25%, meteorological changes – 21%, fatigue – 17%.
Conclusion: This analysis of the trigger factors explored, for the first time, their potential role in inducing HAE
attacks. Our findings might open new perspectives in extending the indications for edema-prophylaxis, and could
contribute to a better understanding of the pathomechanism of HAE attacks.
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Hereditary angioedema (HAE) due to C1-INH deficiency
(HAE-C1-INH) is a rare autosomal dominant disorder.
The deficiency of C1-INH may cause activation of four
closely interrelated (complement, contact-kinin, coagula-
tion, and fibrinolytic) enzyme cascade systems. This may
lead to the release of bradykinin, resulting in recurrent,
paroxysmal angioedema in the subcutis and/or in the
submucosa of the gastrointestinal tract and of the upper
airways. [1-4]. Acute upper airway obstruction caused by
edema may lead to suffocation [5]. The management of the
disease consists of the prevention and therapy of edema-
tous attacks. The diagnosis, management, and follow-up of* Correspondence: farkash@kut.sote.hu
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unless otherwise stated.HAE-C1-INH patients are guided by international recom-
mendations and consensus guidelines based on the latest
scientific findings [6-8].
The genetics of HAE-C1-INH are complex; around
300 mutations have been described so far (see http://
hae.enzim.hu). The correlation between the clinical
phenotype and the genetic background is poor [9-11].
In a proportion of episodes, there are certain background
events, which the patients regard as triggers of attacks. Elu-
cidating the role of these “trigger” factors in initiating
edema formation can help to understand why these attacks
occur. According to empirical observations, physical exer-
tion, mechanical trauma, mental stress, infection, mens-
truation, pregnancy, medical interventions, changes of
weather, and certain medicinal products [3,12-16] are asso-
ciated with an increased risk of a HAE attack. In view of
the pathomechanism of edema formation, the individualtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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stages. The role of trigger factors in the pathophysiology of
edema has not yet been clarified.
Although many of these factors are ubiquitous in
everyday life, HAE-C1-INH patients do not experience
an attack every day. The objective of our study was to
appraise the incidence of various trigger factors, along
with their effect on edematous attacks.
Methods
Stage I of the study
During the initial phase of the study from 2004 to 2010,
we performed diagnostic evaluation (family history, symp-
toms, genetic testing, and complement studies) of 140
HAE-C1-INH patients at the Hungarian HAE Center.
Our survey reviewed the entries made by the subjects in
their standardized Patient Diaries over 7 years. At the ini-
tial visit, patients received individualized information on
the nature of the disease and its possible manifestations.
The locations, severity, trigger factors, and treatment of
HAE attacks were also discussed. Every year, each patient
received a standardized Patient Diary. The latter was
intended for recording the date of onset, severity, location,
and potential trigger factors of the attacks according to
standard criteria, along with the treatment received. The
Patient Diaries were reviewed at the annual follow-up
visits (including evaluation of the relevance and regularity
the entries). At the end of each year, the patients returned
their diaries by mail or in person. Overall, we cannot tell
how accurate these records are as far as the properties of
the events are concerned. The patients affirmed that they
had made efforts to record every attack in the diary.
Nevertheless, ascertaining the occurrence of an attack was
feasible only in the case of those that required treatment
with C1-INH concentrate. This medicinal product was ad-
ministered by medical professionals who documented
their cases and furthermore, the usage of this product
is monitored by the National Health Insurance Funds Ad-
ministration. We found an 88-per-cent agreement be-
tween the entries of the patient diaries and of the medical
records, regarding treatment with C1-INH concentrate.
Analyzing these data, we appraised the characteristics
(e.g. location, trigger factors) of the attacks, as well as
their seasonal and monthly distribution.
Stage II of the study
In the second, prospective stage, we studied 27 patients.
These subjects recorded the occurrence of possible trig-
ger factors every day for seven months –whether or not
they had experienced an attack. In particular, these pa-
tients made a note every day of the occurrence of events
empirically associated with an increased risk of edema
formation. The subjects had received a list of possible
trigger factors along with the patient diary, which theykept from July until December 2011. Thus, patient data
from 7 months were analyzed. In the second phase of
the study, patients were contacted monthly by telephone
to support their compliance with the instructions on
keeping the Patient Diary.
Statistical methods
Statistical analyses were performed with the GraphPad
Prism 4.0 program (GraphPad Software Inc, San Diego,
CA, www.graphpad.com). We used the Chi-square test to
analyze differences between the distribution of trigger fac-
tors and of edema locations. To explore annual distribu-
tion, we summarized the number of attacks occurring
during the four temperate-climate seasons. Furthermore,
we summarized the monthly numbers of the attacks re-
corded each year, from 2004 to 2010. As changes in pa-
tient compliance may introduce differences, we calculated
weighted averages. From these, we determined the mean
annual number of attacks and then, identified the months
with a higher weighted average. Next, we identified the
months with a higher than average number of attacks dur-
ing the seven-year long phase I of the study. All hypoth-
eses were tested against two-directional alternatives and
p < 0.05 was considered significant.
Results
Stage I of the study
Of the 140 HAE-C1-INH patients, six remained
symptom-free until the end of the study. Of the 134 sub-
jects with symptoms, 92 (56 females and 36 males, mean
age 38.35 [range: 12 to 48] years) made records suitable
for analysis to identify trigger factors.
During the seven-year long observation period, these
92 patients recorded information on 3176 episodes.
Sixty-five per cent (2187/3176) of these were subcutane-
ous, and 35% (1151/3176) were submucosal (937 ab-
dominal and 214 upper airway) attacks. Seventy-one per
cent (2256/3176) of the attacks occurred in female pa-
tients. In 162 instances, edema formation affected multiple
locations – that is, involved subcutaneous and submucosal
tissues concomitantly. Eight of the 92 patients could not
detect any potential trigger in their lives, whereas 84 sus-
pected at least one such factor.
The trigger factors identified by the patients
The subjects identified several trigger factors (Table 1),
most commonly physical exertion (66 subjects), followed
by mental stress, and mechanical trauma (55–55 patients).
Trigger factors and total attack number
The subjects could identify a trigger factor in 30% (953/
3176) of all recorded attacks, and in 23.64% of subcuta-
neous, 38.13% of abdominal, and 28.50% of upper airway
episodes. The following trigger factors were identified:
Table 1 The trigger factors of HAE attacks, ranked by
frequency
Trigger factor Number of involved patients
(Σn = 92)
Physical exertion 66
Mental stress 55
Mechanical trauma 55
Infection 41
Weather changes 29
Menstruation 25
Foodstuffs 18
Dental procedures 15
Fatigue/exhaustion 8
Medical procedures 7
Pregnancy 6
Estrogen-containing oral
contraceptive use
3
Others
Ovulation 2
Insect bites 2
Allergy 2
Cosmetics 2
Treatment with ACEI 1
Thermal injury 1
Gastric acid hypersecretion 1
Prolonged voluntary suppression of
micturition
1
Table 2 The distribution of trigger factors by attack
locations
Attacks with
known trigger
factor
Subcutaneous
episodes
Abdominal
episodes
Upper
airway
episodes
Mental stress 21 15 27 22
Menstruation 18 11 17 26
Physical exertion 17 24 13 -
Weather changes 15 14 15 8
Infection 11 10 12 26
Mechanical
trauma
11 17 1 7
Fatigue 6 4 8 8
Dental
procedures
- 2 - -
Foodstuffs - 2 6 -
Other 3 1 1 3
The values presented in the table are percentages (%).
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changes (15%), menstruation (18% in the female popula-
tion), infection (11%), trauma (11%), fatigue (6%), preg-
nancy (4% in the female population), others (3%)
(Table 2).Trigger factors and location of attacks
We analyzed the attacks of different (subcutaneous, ab-
dominal, or upper airway) locations according to the dis-
tribution of their trigger factors (Table 2). Subcutaneous
edema was most often induced by physical exertion (24%).
The leading trigger factor of abdominal attacks was mental
stress (27%), whereas in the case of upper airway edema,
infection (26%) was followed by menstruation (26%). The
chi-square test showed a significant (p < 0.0001) difference
between the distributions of the trigger factors of the
edematous attacks of different locations.The monthly and seasonal distribution of attacks
The weighted average of the number of submucosal at-
tacks was higher in January, August, and October than
in the other months of the year. The number ofsubcutaneous attacks peaked in November, and episodes
without an identifiable trigger factor occurred most
often in March and October. We observed a similar dis-
tribution of the attacks induced by mental stress.Stage II of the study
The second, prospective stage of our study included 27
patients (5 males and 22 females, mean age: 36.26
[range: 9 to 58] years). These subjects had been making
diary entries to record possible trigger factors every day
for seven months – whether or not they had experienced
an attack. During the seven months of Stage II, the pa-
tients identified 882 possible trigger factors and recorded
365 attacks. Two hundred forty-six of the latter occurred
on days when the patients could identify at least one
“likely” trigger factor. Overall, 67% of the attacks were
associated with a suspected trigger. Of the 365 attacks,
234 affected the subcutis, 114 were abdominal, and 17
occurred in the upper airways.The likelihood of an attack associated with individual
trigger factors
We examined the association between the individual
trigger factors and the occurrence of attacks. The follow-
ing ratios were observed: menstruation 38/60 (63%), in-
fection 28/74 (38%), mental stress 53/199 (26%), physical
exertion 41/167 (25%), weather changes 58/274 (21%),
and fatigue 16/92 (17%). According to the patients,
trauma occurred on seven occasions, and an attack en-
sued in five of these. Food was the suspect trigger fac-
tor in nine cases, of which seven were associated with
an attack, which indeed might have resulted from the
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ity of the infections involved the upper airways. One
patient reported urinary tract infection, whereas enter-
itis was the likely trigger factor in another. Table 3
shows the number of attacks induced by the individual
triggering factors for each patient.The relationship between trigger factors and attack
locations
We examined the individual trigger factors of attacks in-
volving different locations. Table 4 shows the trigger fac-
tors according to the location of the attack. Physical
exertion usually induced a subcutaneous attack, whereas
menstruation triggered submucosal edema formation.
The chi-square test showed a significant (p < 0.0001) re-
lationship between the type of the trigger factor and the
location of the attack.Table 3 The number of attacks induced by the individual trig
Patient no. Menstruation Infection Mental stress P
1 8/8 1/2 3/6
2 - 1/1 0/6
3 3/5 0/8 2/7
4 7/7 - -
5 0/1 1/15 3/14
6 - 5/8 6/9
7 0/7 0/1 1/1
8 - 1/1 5/9
9 - - -
10 4/4 - 7/7
11 3/4 0/4 3/48
12 - 3/5 1/2
13 - 5/8 7/22
14 2/4 0/1 -
15 - - 4/14
16 M - - -
17 M - 4/4 -
18 - 1/2 1/7
19 0/1 0/2 0/17
20 3/6 1/3 3/15
21 - 0/3 1/4
22 M - - -
23 M - 2/2 -
24 5/5 - 2/2
25 2/2 1/1 -
26 1/6 0/1 0/2
27 M - 2/3 4/7
The letter ‘M’ indicates male patients.The likelihood of edematous attacks in patients
undergoing/not receiving long-term prophylaxis
The likelihood of an attack triggered by infection, stress,
physical exertion, and weather changes was higher in pa-
tients undergoing than in those not receiving long-term
prophylaxis (LTP) Table 5. Such a comparison was im-
possible during Stage I of the study, because the changes
made to the therapeutic regimen during the observation
period precluded defining sufficiently homogenous treat-
ment groups.Discussion
Our study explored trigger factors during the long-term
follow-up of our patient population. This is the first, sys-
tematic review of the possible role of these factors in
HAE attacks. Ninety-one per cent of the subjects could
identify a trigger factor – most often physical exertiongering factors for each patient
hysical exertion Weather changes Fatigue Unknown
1/2 2/16 1/2 4
- 0/7 - 1
1/3 4/48 1/3 1
- - - 42
- - 2/21 -
2/4 10/30 1/4 2
1/24 - 0/1 -
1/3 5/14 2/6 15
4/4 - - -
- - - 14
5/53 2/3 0/2 -
6/27 15/65 2/13 -
- 0/2 0/1 -
- 1/1 - -
2/2 1/1 0/1 4
5/5 - - 1
0/2 - - 3
0/6 0/3 0/12 2
0/4 0/11 0/11 -
0/2 0/6 3/7 3
- - 0/4 -
8/8 9/9 - 4
1/1 3/3 1/1 12
- 3/3 - 6
3/12 - - 4
- 1/14 - -
1/5 2/38 3/3 1
Table 4 The distribution of the attacks induced by
various trigger factors, by location
Trigger factor Subcutaneous
episodes
Abdominal
episodes
Upper airway
episodes
Menstruation 11 21 6
Mental stress 35 12 6
Physical exertion 38 3 0
Weather changes 49 8 1
Infection 14 10 4
Mechanical trauma 5 0 0
Fatigue 15 1 0
Foodstuffs 0 7 0
Non-explorable
trigger factor
67 52 0
The values presented in the table are percentages (%).
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(59%). The patients detected a trigger factor – most
commonly mental stress – in one-third of the edema-
tous episodes they had experienced. Therefore, providing
mental health support or antidepressant treatment may
be considered when necessary. It is a novel observation
that in the case of attacks with a particular trigger, the
patients held weather changes responsible in one-sixth
of all these episodes. A variety of major trigger factors
induced attacks in different locations.
The subjects suspected a trigger factor most often in
relation to abdominal attacks. Physical exertion most
commonly provoked subcutaneous edema, whereas
mental stress induced abdominal attacks for the most
part. Infection and menstruation were responsible for
the majority of upper airway episodes. The frequency of
mucosal symptoms was lower than usually reported
[17-19]. Episodes involving multiple locations were also
less common. The background of these phenomena is
not clear; possible explanations include ethnic diversity
and/or differences in lifestyle. We detected a similarTable 5 The likelihood of edematous attacks in patients
undergoing/not receiving long-term prophylaxis
Trigger factor Patients not
receiving
long-term
prophylaxis
Patients
receiving
long-term
prophylaxis
Whole
population
Menstruation 62.5% 65% 63%
Infection 23.7% 52.8% 38%
Mental stress 12.9% 53.7% 26%
Physical exertion 12% 54% 25%
Weather changes 15.4% 28% 21%
Fatigue 18% 16.1% 17%
Non-explorable
trigger factor
35.3% 32.5% 32.6%trend in a previous study conducted on a group of
Hungarian and German patients: the incidence of ab-
dominal attacks was significantly – three times – higher
among German patients [20].
The presence of a trigger factor, suspected by the patient
as the cause of edema, does not necessarily lead to an ac-
tual attack. Among the trigger factors identified, menstru-
ation was most likely to lead to edema formation (in 68%
of cases). In a subset of patients, menstruation was a typ-
ical inducer of edematous episodes. In this study, we
found that certain trigger factors were more likely to in-
duce attacks in patients undergoing than in those not re-
ceiving long-term prophylaxis. This is possibly explained
by the fact that the former have more severe disease
(which requires LTP) and as such, they are more suscep-
tible to the influence of trigger factors. Counseling these
patients about possible trigger factors is thus indispens-
able, as it enables them to prepare for future attacks.
The knowledge about the role of trigger factors makes
it possible to change the lifestyle of the patient and to
introduce individualized management.
Conclusions
The exact role of trigger factors needs further clarifica-
tion, because they do not necessarily induce an attack.
Thus, predicting the occurrence of edematous episodes
in HAE-C1-INH patients remains unfeasible. Neverthe-
less, with the knowledge of these factors is important,
because primary prevention – that is, avoiding specific
trigger factors – is possible in a proportion of cases. Ac-
cording to our findings, menstruation – a potent trigger
factor – appears another suitable target for short-term
drug prophylaxis. To determine the optimum timing of
the latter, the propensity for edema formation during the
menstrual cycle should be explored further. Early diag-
nosis, the identification of trigger factors, timely recogni-
tion of prodromal and initial symptoms, counseling, and
state-of-the art management may help HAE-C1-INH pa-
tients to live a normal life.
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